Form 4: Gilead Sciences CFO Andrew Dickinson Reports Stock Sale

Gilead Sciences' CFO, Andrew Dickinson, sold 2,500 shares of common stock at a price of $104.09 per share on February 18, 2025, according to a Form 4 filing with the SEC.

Summary

• Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc., reported a transaction involving the company's common stock.
• On February 18, 2025, Dickinson sold 2,500 shares of Gilead Sciences' common stock at a price of $104.09 per share.
• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 29, 2024.
• Following the reported transaction, Dickinson beneficially owns 169,061 shares of Gilead Sciences' common stock.
• The filing also reflects an adjustment to Dickinson's holdings due to shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports a routine stock sale under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company's prospects.

Industry Context

Executive stock sales are a common occurrence in publicly traded companies and are often scrutinized by investors for insights into management's perspective on the company's future prospects. However, sales under pre-arranged trading plans like Rule 10b5-1 are generally viewed as less indicative of management sentiment, as they are often established for personal financial planning reasons.

Comparison to Industry Standards

• Executive stock sales are a common practice across the pharmaceutical industry.
• Companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK) also see regular Form 4 filings from their executives.
• The volume and frequency of these transactions can vary based on individual executive compensation plans and personal financial strategies.
• It's important to compare the size and frequency of Dickinson's sales to those of executives at comparable companies to gauge whether there's anything unusual about this transaction.

Stakeholder Impact

• The stock sale could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• However, given the relatively small size of the transaction compared to the company's overall market capitalization, the impact is likely to be minimal.

Key Dates

Keywords

Gilead Sciences, Andrew Dickinson, Form 4, SEC Filing, Stock Sale, Rule 10b5-1, CFO, GILD, Employee Stock Purchase Plan